{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:38:55Z","timestamp":1782297535971,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jvir.2018.09.020","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T18:06:25Z","timestamp":1551117985000},"page":"298-304.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis"],"prefix":"10.1016","volume":"30","author":[{"given":"Alexander Y.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Frantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayson","family":"Brower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2018.09.020_bib1","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvir.2018.09.020_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju413","article-title":"nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial","author":"Goldstein","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jvir.2018.09.020_bib3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s12325-016-0327-4","article-title":"nab-Paclitaxel plus gemcitabine versus gemcitabine in patients with metastatic pancreatic adenocarcinoma: Canadian subgroup analysis of the phase 3 MPACT trial","volume":"33","author":"Tehfe","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.jvir.2018.09.020_bib4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1186\/s12885-016-2798-8","article-title":"Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)","volume":"16","author":"Vogel","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jvir.2018.09.020_bib5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvir.2018.09.020_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jvir.2018.09.020_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/1756283X17705328","article-title":"Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer","volume":"10","author":"Rahman","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jvir.2018.09.020_bib8","series-title":"NCCN Guidelines: Pancreatic Adenocarcinoma, version 2.2107","author":"National Comprehensive Cancer Network","year":"2017"},{"key":"10.1016\/j.jvir.2018.09.020_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/1758834016688816","article-title":"Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy","volume":"9","author":"Kipps","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jvir.2018.09.020_bib10","doi-asserted-by":"crossref","first-page":"931","DOI":"10.5858\/2008-132-931-MPOCRF","article-title":"Metastatic patterns of cancers: results from a large autopsy study","volume":"132","author":"Disibio","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jvir.2018.09.020_bib11","doi-asserted-by":"crossref","first-page":"e1012","DOI":"10.1097\/MD.0000000000001012","article-title":"Initial metastatic site as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma","volume":"94","author":"Kim","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jvir.2018.09.020_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s12885-016-2552-2","article-title":"Incorporating yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcinoma: a single center experience","volume":"16","author":"Kim","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jvir.2018.09.020_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2967\/jnumed.115.165613","article-title":"Use of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancer","volume":"57","author":"Michl","year":"2016","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jvir.2018.09.020_bib14","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1186\/s12885-015-1822-8","article-title":"Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma","volume":"15","author":"Gibbs","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jvir.2018.09.020_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000355821","article-title":"Radioembolization with yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors","volume":"86","author":"Michl","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.jvir.2018.09.020_bib16","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/548.6515","article-title":"Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: results from a pilot study","volume":"96","author":"Cao","year":"2010","journal-title":"Tumori"},{"key":"10.1016\/j.jvir.2018.09.020_bib17","first-page":"84","article-title":"Chemotherapy with yttrium 90 microsphere selective internal radiation treatment and selective external radiation treatment in patients with metastatic pancreatic cancer","volume":"2","author":"Gulec","year":"2009","journal-title":"J\u00a0Intervent Oncol"},{"key":"10.1016\/j.jvir.2018.09.020_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11547-010-0496-1","article-title":"Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases","volume":"115","author":"Cianni","year":"2010","journal-title":"Radiol Med"},{"key":"10.1016\/j.jvir.2018.09.020_bib19","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s00330-006-0508-7","article-title":"Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres","volume":"17","author":"Jakobs","year":"2007","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jvir.2018.09.020_bib20","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.ijsu.2014.07.014","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"12","author":"Vandenbroucke","year":"2014","journal-title":"Int J Surg"},{"key":"10.1016\/j.jvir.2018.09.020_bib21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jvir.2018.09.020_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijrobp.2006.11.060","article-title":"Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium","volume":"68","author":"Kennedy","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jvir.2018.09.020_bib23","first-page":"178","article-title":"Radioembolization of hepatic tumors","volume":"5","author":"Kennedy","year":"2014","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.jvir.2018.09.020_bib24","series-title":"SIR-Spheres\u00ae microspheres (yttrium-90 microspheres) [package insert]","author":"SIR-Spheres","year":"2017"},{"key":"10.1016\/j.jvir.2018.09.020_bib25","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.26191","article-title":"Prognostic factors and prevention of radioembolization-induced liver disease","volume":"57","author":"Gil-Alzugaray","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2018.09.020_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jvir.2010.10.029","article-title":"Research reporting standards for radioembolization of hepatic malignancies","volume":"22","author":"Salem","year":"2011","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2018.09.020_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jvir.2016.09.024","article-title":"Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions","volume":"28","author":"Padia","year":"2017","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2018.09.020_bib28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jvir.2015.12.752","article-title":"Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria","volume":"27","author":"Gaba","year":"2016","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2018.09.020_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jvir.2018.09.020_bib30","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","article-title":"The pancreas cancer microenvironment","volume":"18","author":"Feig","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jvir.2018.09.020_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jmri.10337","article-title":"Liver metastases from pancreatic adenocarcinoma: MR imaging characteristics","volume":"18","author":"Danet","year":"2003","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.jvir.2018.09.020_bib32","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/bjc.2017.67","article-title":"Quality-adjusted survival with combination nal-IRI+5-FU\/LV vs 5-FU\/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis","volume":"116","author":"Pelzer","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jvir.2018.09.020_bib33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semradonc.2011.05.003","article-title":"Hepatic radiation toxicity: avoidance and amelioration","volume":"21","author":"Guha","year":"2011","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jvir.2018.09.020_bib34","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.semradonc.2017.04.002","article-title":"Radiation-induced liver toxicity","volume":"27","author":"Munoz-Schuffenegger","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jvir.2018.09.020_bib35","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MEG.0000000000000772","article-title":"Radioembolization-induced liver disease: a systematic review","volume":"29","author":"Braat","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jvir.2018.09.020_bib36","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/hep.29207","article-title":"Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review","volume":"66","author":"Sangro","year":"2017","journal-title":"Hepatology"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044318315100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044318315100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T06:03:31Z","timestamp":1760940211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044318315100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1051044318315100"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2018.09.020","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2018.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 SIR, 2018","name":"copyright","label":"Copyright"}]}}